Stock News Alert: Fulcrum Therapeutics (NASDAQ:FULC)

January 13, 2020

Fulcrum Therapeutics (NASDAQ:FULC) stock observed trading -4.09% off 52-week high price. On the other end, the stock has been noted 323.57% away from low price over the last 52-weeks. The stock disclosed a move of 53.90% away from 50 day moving average and 75.24% away from 200 day moving average. Moving closer, we can see that shares have been trading 20.11% off 20-day moving average. It has market cap of $426.47M.

On Jan. 6, 2020, Fulcrum Therapeutics (NASDAQ:FULC) a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, revealed the appointment of Katina Dorton to the Company’s board of directors and as chair of the audit committee.

We are excited to have Katina join the team, said Robert J. Gould, Ph.D., Fulcrum’s president and chief executive officer. Her appointment reflects our commitment to ensuring we have a broad mix of skills and perspectives on Fulcrum’s board. We look forward to benefiting from Katina’s guidance and leadership as we continue to make important progress with losmapimod and expand our pipeline.

Ms. Dorton most recently served as Executive Vice President and Chief Financial Officer at Repare Therapeutics, an oncology company focused on DNA damage repair and synthetic lethality, and prior to that, Chief Financial Officer at AVROBIO, a gene therapy company focused on rare disease. Previously, Ms. Dorton spent more than 15 years as an investment banker, advising companies and their Boards on capital markets, fund raising, mergers and acquisitions and other strategic transactions. She was a Managing Director at Morgan Stanley and a Managing Director at Needham & Co. She also served as an attorney in private practice at Sullivan & Cromwell. Ms. Dorton currently is on the Board of Directors at US Ecology, an environmental services company. Ms. Dorton holds a J.D. from the University of Virginia School of Law, an M.B.A. from George Washington University and a B.A. from Duke University.

Fulcrum’s unique approach to developing small molecule therapies that target the root cause of serious genetic disorders offers great promise to patients and their families, said Ms. Dorton. I look forward to working with the board and company leadership as Fulcrum advances its pipeline.

The USA based company Fulcrum Therapeutics moved with change of 1.31% to $18.51 with the total traded volume of 92284 shares in recent session versus to an average volume of 61.97K shares. The stock was observed in the 5 days activity at 16.12%. The one month performance of stock was 43.38%. FULC’s shares are at 247.28% for the quarter is now at 11.24% since this point in 2018.   The average volatility for the week and month was at 10.05% and 12.48% respectively. There are 23.04M shares outstanding and 21.30M shares are floated in market.

Leave a Reply

Your email address will not be published. Required fields are marked *